VIA
CYTK icon

Virtus Investment Advisers’s Cytokinetics CYTK Stock Holding History

Virtus Investment Advisers’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.41M Buy
16,577
+12,274
+285% +$881K 0.33% 132
2026
Q1 		$284K Buy
4,303
+56
+1% +$3.56K 0.08% 291
2025
Q4 		$270K Buy
4,247
+819
+24% +$50.9K 0.07% 293
2025
Q3 		$188K Buy
3,428
+596
+21% +$24.6K 0.05% 260
2025
Q2 		$93.6K Sell
2,832
-438
-13% -$15.2K 0.03% 360
2025
Q1 		$131K Buy
+3,270
New +$150K 0.04% 374
2024
Q1 		– Sell
-4,718
Closed -$394K – 355
2023
Q4 		$394K Sell
4,718
-3,946
-46% -$143K 0.3% 107
2023
Q3 		$255K Buy
8,664
+720
+9% +$24K 0.17% 146
2023
Q2 		$259K Sell
7,944
-4,870
-38% -$180K 0.18% 157
2023
Q1 		$451K Sell
12,814
-1,767
-12% -$72.1K 0.32% 101
2022
Q4 		$668K Hold
14,581
– – 0.45% 60
2022
Q3 		$706K Buy
+14,581
New +$702K 0.32% 50

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Virtus Investment Advisers's CYTK Position: Q2 2026 in Review

Virtus Investment Advisers increased its Cytokinetics (CYTK) stake by 285% in Q2 2026, buying an estimated $881K and bringing the position to 16,577 shares worth $1.41M. The position accounts for 0.33% of the portfolio, ranked #132.

Virtus Investment Advisers first reported a position in CYTK in Q3 2022 and has held it in 12 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Virtus Investment Advisers held 16,577 shares of Cytokinetics worth $1.41M as of Q2 2026.
  • Virtus Investment Advisers bought 12,274 Cytokinetics shares in Q2 2026, an estimated $881K.
  • Cytokinetics made up 0.33% of Virtus Investment Advisers's portfolio in Q2 2026, its #132 holding.
  • Virtus Investment Advisers first reported a position in Cytokinetics in Q3 2022 and has held it in 12 quarters since.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.